Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Recent clinical studies have demonstrated a reduction of irinotecan (CPT-11) gastrointestinal
toxicities when the CPT-11 is administered in combination with thalidomide in patients with
diagnosis of gastric cancer. The main purpose of this study is to investigate the efficacy
and safety of thalidomide and CPT-11 in advanced gastric cancer. The investigators will also
manage to find out the possible interactions between CPT-11 pharmacokinetics and thalidomide
to explain the previously described gastrointestinal toxicity reduction.
Phase:
Phase 4
Details
Lead Sponsor:
Wang Jufeng
Collaborators:
Henan Provincial Hospital Henan Provincial People's Hospital Second Affiliated Hospital of Zhengzhou University The First Affiliated Hospital of Henan University of Science and Technology The First Affiliated Hospital of Zhengzhou University